75
Views
1
CrossRef citations to date
0
Altmetric
Miscellaneous

Therapeutic anticancer antibodies

&
Pages 177-222 | Published online: 02 Mar 2005

Bibliography

  • EHRLICH P: On immunity with special reference to cell life. Proc. Roy Soc. Lond. (1900) 66:424.
  • JERNE NK: The natural selection theory of antibody formation. Proc. Nat. Acad. Sci. USA (1955) 41:849.
  • BURNET FM: A modification of Jurne's theory of antibody production using the concept of clonal selection. Aust.' Sci. (1957) 20:67.
  • POTTER M: Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev (1972) 52:631.
  • KRAUSE RM: The search for antibodies with molecular uniformity. Adv. Immunol (1970) 12:1.
  • KOHLER G, MILSTEIN C: Continuous cultures of fused cells producing antibodies of predefined specificity. Nature (1975) 256:495–497.
  • HIMMELWEIT F (Ed.): The collected papers of Paul Ehrlich. Immunology and Cancer Res. (Vol. 4, Pergamon Press, London (1957).
  • PRESSMAN D, KORNGOLD L: The in vivo localisation of anti-Wagner-osteogenic-sarcoma antibodies. (1953) Cancer 6:619.
  • BALE WE SPARL F, GOODLAND RL, WOLFE DE: In vivo and in vitro studies of labelled antibodies against rat kidney and Walker carcinoma. Proc. Soc. Exp. Biol. Med. (1955) 89:564–568.
  • QUINONES J, MIZEJEWSKI G, BEIERWALTES WH: Choriocarcinoma scanning using radiolabelled antibody to chorionic gonadotrophin. I Nuc. Med (1971) 12:69–75.
  • MACH JP, CARREL S, MERENDA C, SORDAT B, CEROTTINI JC: In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 248:704–706.
  • DYKES PW, HINE KR, BRAD WELL AR et al.: Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br. Med. .1. (1980) 1:220.
  • BEGENT RHJ, SEARLE F, STANWAY G et al.: Radioimmunolocalization of tumours by external scintigraphy after administration of 131 I antibody to human chorionic gonadotropin: preliminary communication. J. R. Soc. Med. (1980) 73:624.
  • BOMANJI J, HUNGERFORD JL, GRANOWSKA M, BRITTON KE: Radioimmunoscintigraphy of ocular melanoma with Tc-99m labelled cutaneous melanoma antibody fragments. Br. J. Ophthalinol (1987) 71:651.
  • BAUM RP, BOECKMANN W SCHULDES H et al.: In-111 anti-CEA monoclaonal antibody SPECT imaging for the identification of lymph node metastases of bladder carcinoma. Eur J. Nucl. Med. (1990) 16:417.
  • EPENETOS AA, SNOOK D, HOOKER G et al.: 111Indium labelled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of testis, ovary, and cervix. Lancet (1985) 350.
  • BUCHEGGER F, HASKELL CM, SCHREYER M et al.: Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J. Exp. Med. (1983) 158:413.
  • WAHL RL, PARKER CW, PHILPOTT G: Improved radio-imaging and tumour localisation with monoclonal F(ab') 2. J. Nucl. Med. (1983) 24:316.
  • GERRETSEN M, QUAK JJ, SUH JS et aL: Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab') 2 fragment in xenografts of human squamous cell carcinoma of the head and neck and the vulva as compared to monoclonal antibody E48 IgG. Br. J. Cancer (1991) 63:37–44.
  • SICCARDI AG, BURAGGI GL, CALLEGARO L et al.: Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab% fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res. (1989) 49:3095–3105.
  • DELALOYE B, BISCHOFF- DELALOYE A, BUCHEGGER F et al.: Detection of colorectal carcinoma by emission computerised tomography after injection of 123I-labelled Fab and F(ab')2 fragments from monoclonal anti-carcinembryonic antigen antibodies. J. Gun. Invest. (1986) 7:301–306.
  • DURBIN H, MILLIGAN EM, MATHER S, TUCKER DF, RAYMOND R, BODMER W: Monoclonal antibodies to placental alkaline phosphatase: preclinical evaluation in a human xenograft tumour model of Rab') 2 and Fab fragments. hat. J. Cancer (1988) 42\(Suppl. 2):59–66.
  • LARSON SM, CARRASQUILLO JA, REYNOLDS JC et al.: Therapeutic applications of radiolabelled antibodies: current situation and prospects Nucl. Med. Biol. (1986) 13:207.
  • GIVOL D: The minimal antigen-binding fragment of antibodies-Fv fragment. Mol brununol (1991) 28:1379–1386.
  • PLUCKTHUN A: Antibody engineering: advances in the use of Escherichia coil expression systems. Biotechnology (1991) 9:545–551.
  • HERICOURT J, RICHET C: (1895) 120:948–952.
  • BOERI DG: (1901) 6:73.
  • MURRAY G: Experiments in immunity in cancer. Can. Med. Ass. .1. (1958) 79:249–259.
  • BUINAUSKAS P, MCCREDIE JA, BROWN ER, COLE WH: Arch. Surg. Chicargo (1959) 79:432–437.
  • SUMMER WC, FORAKER AG: Cancer (1960) 13:79–81.
  • LASZLO J, BUCKLEY CE, AMOS CB: Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood (1968) 31:104–110.
  • HELLSTROM I, HELLSTROM KE. Cell-mediated reactivity to human tumour-type associated antigens: does it exist? J. Biol. Response Mod (1983) 2:310–320.
  • KUNKEL HG, MANNIK M, WILLIAMS RC: Individual antigenic specificity of isolated antibodies. Science (1963) 140:1218–1220.
  • GEHA RS: Regulation of the immune response by idiotype anti-idiotype interaction. New Engl. J. Med (1981) 305:25–35.
  • TSUJISAKI M, IMAI K, TOKUCHI S et al: Induction of antigen-specific immune response with the use of anti-idiotypic monoclonal antibodies to anti-carcinoembryonic antigen antibodies. Cancer Res. (1991) 51:2599–2604.
  • BROWN SL, MILLER RA, HORNING SJ et al.: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with a interferon. Blood (1989) 73:651–661.
  • PRESSMEN D, KEIGHLEY G: I brununol (1948) 59:141–146.
  • BEIERWALTERSWH: M Mich. Med. Bull (1956) 20:284.
  • RAINSBURY RN, WESTWOOD JH: Tumor localisation with monoclonal antibody radioactively labeled with metal chelate rather than iodine. Lancet (1982) 12:1347.
  • VRIESENDORP HM, HERPST JM, GERMACK MA et al.: Phase I-II studies of yttrium-labeled anti ferritin treatment for end-stage Hodgkin's disease including Radiation Therapy Oncology Group. I Clin. Oncol (1991) 9:918–928.
  • KAMINSKI MS, FIG LM, ZASANDY KR et al.: Imaging, dosimetry and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. I Gin. Oncol (1992) 10:1696–1711.
  • PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support. New Engl. J. Med (1993) 325:1219–1224.
  • PIMM MV, ROBIN RA, EMBLETON MJ et al.: A bispecific monoclonal antibody against methotrexate and a human tumour-associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Br. .1. Cancer (1990) 61:508–513.
  • SIEVERS EL: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin. Biol .Thei: (2001) 1:893–901.
  • WALDMANN TA: Monoclonal antibodiesin diagnosis and therapy. Science (1991) 252:1657–1662.
  • EMBLETON MJ, CHARLEWSTON A, ROBINS RA, PIMM MV, BALDWIN RW: Recombinant ricin A chain cytotoxicity against carcinoembryonic antigen-expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin B chain. Br.! Cancer (1991) 63:670–674.
  • SPOONER RA, LORD JM: Expression ofantibody-ricin A chain fusion in mammalian cells. In: Monoclonal antibodies: applications in clinical oncology Epenetos AA (Ed.), Chapman and Hall medical, London (1991):65–77.
  • PASTAN I, CHAUDHARY V, FITZGERALD DJ: Recombinant toxins as novel therapeutic agents. Ann. Rev Biochem (1992) 61:331–354.
  • RYBAK SM, SAXENA SK, ACKERMAN EJ, YOULE RJ: Cytotoxic potential of ribonuclease hybrid proteins. Biol. Chem (1991) 226:21202–21207.
  • LINARDOU H, DEONARAIN MP, SPOONER RA, EPENETOS AA. Deoxyribonuclease I (DNAseI). A novel approach for targeted cancer therapy. Cell Biophys. (1994) 24–25:243–248.
  • SOLER-RODRIGUEZ AM, GHETIE MA, OPPENHEIMER-MARKS N, URH JW, VITETTA ES: Ricin A-chain and ricin A-chain immunotwdns rapidly damage human endothelial cells: implications of vascular leak syndrome. Exp. Cell. Res (1993) 206:227–234.
  • GOULD BJ, BOROWITZ MJ, GROVES ES et al.: Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. Natl Cancer Inst. (1989) 81:775–781.
  • FITZGERALD D, PASTAN I: Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst (1989) 81:1455–1463.
  • SPITLER LE, DELRIO M, KHENTIGAN A et al.: Therapy of patients with malignant-melanoma using a monoclonal antimelanoma antibody-ricin a chain immunotwdn. Cancer Res. (1987) 47:1717–1723.
  • SPOONER RA, MURRAY S, ROWLINSON-BUSZA G, DEONARAIN MP, CHU AC, EPENETOS AA: Genetically engineered antibodies for diagnostic pathology. Hum. Pathol (1994) 25:606–614.
  • YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52:3402–3408.
  • SKERRA A, PLUCKTHUN A: Assembly ofa functional immunoglobulin Fv fragment in Escherichia coll. Science (1988) 240:1038–1040.
  • WARD ES, GUSSOW D, GRIFFITHS AD et al.: Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coil. Nature (1989) 341:544–546.
  • HUSTON JS, LEVINSON D, MUDGETT-HUNTER M et al.: Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E colt Proc Natl. Acad. Sci. USA (1988) 85:5879–5883.
  • BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single chain antigen-binding proteins. Science (1988) 242:423–426.
  • HOO WFS, LACY MJ, DENZIN LK et al.: Characterisation of a single chain T-cell receptor expressed in E. coli Proc. Natl. Acad. Sci. USA. (1992) 89:4759–4763.
  • EPPS LA, SUN L, ARE VALO M et al.: Technetium (Tc-99m) labelled genetically engineered chimeric 17-1A G4K/ Metallothionein antibody. Nucl. Med. (1989) 30:794.
  • NEDELMAN MA, SHEALY DJ, BOUTIN R et al: Rapid infarct imaging with a 99mTc antimyosin scFv fragment: Evaluation in a canine model of acute myocardial infarction. Nuclear Med. (1993) 34(2):234–241.
  • SEETHARAM S, CHAUDHARY VK, FITZGERALD DJ, PASTAN I: Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. (1991) 266:17376–17381.
  • HUSTON JS, TAI MS, MUD GETT-HUNTERM et al.: Protein Engineering of single-chain Fv analogues and fusion proteins. In: Molecular design and modeling: concepts and applications, part B. Methods in Enzymology Langone If (Ed.), (1991) 203:46–88.
  • DUCHOSAL MA, EMING SA, FISCHER P et al.: Immunization of hu-PBL-SCID mice and rescue of human monoclonal Fab fragments through combinatorial libraries. Nature (1992) 355:258–262.
  • RICHARDS J, AUGER J, PEACE D et al.:Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res. (1999) 59:2096–2101.
  • KIPRIYANOV SM, COCHLOVIUS B, SCHAFER HJ et al: Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. I Immunol (2002). 169:137–144.
  • COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ et al.: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res. (2000) 60:4336–4341.
  • KODAMA H, SUZUKI M, KATAYOSE Y et al.: Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol Lett. (2002) 81:99–106.
  • RENNER C, PFREUNDSCHUH M: Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. I Hematother. (1995) 4:447–451.
  • OHMI Y, SHIKU H, NISHIMURA T: Tumor-specific targeting of T helper Type 1 (Thl) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody. Cancer Immunol Immunother. (1999) 48:456–462.
  • LUM LG, SEN M: Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside. Acta Haematol (2001) 105: 130–136.
  • ZHU Z, LEWIS GD, CARTER P: Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells. Int. I Cancer (1995) 62:319–324.
  • JUNG G, BRANDL M, EISNER W et al:Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. Cancer (2001) 91:225–230.
  • RICE DC, CHAPOVAL Al, PORTER L, NELSON H: Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody. Cancer Immunol Immunother. (1999) 48:230–238.
  • DAVICO BONINO L, DE MONTE LB, SPAGNOLI GC et al.: Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma. Intl Cancer (1995) 61: 509–515.
  • BERNHARD H, KARBACH J, STRITTMATTER W, MEYER ZUM BUSCHENFELDE KH, KNUTH A: Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. hat. I Cancer (1993) 55:465–470.
  • HOMBACH A, TILLMANN T, JENSEN M et al.: Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/ CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. bninunother (1997) 20:325-333. ao.SHEN GL, LI JL, VITETTA ES: Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. brimunol. (1994) 152:2368–2376.
  • LIAO KW, LO YC, ROFFLER SR: Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. (2000) 7:339–347.
  • FOSS FM, RAUBITSCHECK A, MULSHINE JL et al.: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin. Cancer Res (1998) 4:2691–2700.
  • ZIMMER AM, ROSEN ST, SPIES SM et al.: Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-1-31-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. Nucl. Med. (1988) 29:174–180.
  • RAVEL S, COLOMBATTI M, CASELLAS P: Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells. Blood (1992) 79:1511–1517.
  • HERTLER AA, SCHLOSSMAN DM, BOROWITZ MJ, BLYTHMAN HE, CASELLAS P, FRANKEL AE: An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. hat. J. Cancer (1989) 43: 215–219.
  • RAVEL S, CASELLAS P: Internalization of the cytotoxic molecules of T101 F (ab')2- (ricin-A-chain) immunotoxin into human T-leukemic cells. Ear Biochem. (1990) 192:469–473.
  • MA D, MCDEVITT MR, BARENDSWAARD E et al.: Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia (2002) 16: 60–66.
  • IDEN DL, ALLEN TM: In vitro and M vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta. (2001) 1513:207–216.
  • EK O, GAYNON P, ZEREN T, CHELSTROM LM, MYERS DE, UCKUN FM: Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leak. Lymphoma (1998) 31:143–149.
  • MYERS DE, SICHENEDER A, CLEMENTSON D et al.: Large scale manufacturing of B43 (anti- CD 19) - genistein for clinical trials in leukemia and lymphoma. Leak. Lymphoma (1998) 29:329–338.
  • FLAVELL DJ, NOSS A, PULFORD KA,LING N, FLAVELL SU: Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. (1997) Cancer Res. 57: 4824–4829.
  • FLAVELL DJ, BOEHM DA, EMERY L, NOSS A, RAMSAY A, FLAVELL SU: Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int. J. Cancer (1995) 62:337–344.
  • GHETIE MA, PODAR EM, GORDON BE, PANTAZIS P, UHR JW, VITETTA ES: Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer (1996) 68:93–96.
  • GIDLOF C, DOHLSTEN M, LANDO P, KALLAND T, SUNDSTROM C, TOTTERMAN TH: A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Blood (1997) 89:2089–2097.
  • SHAH SA, HALLORAN PM, FERRIS CA et al.: Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. (1993) 53:1360–1367.
  • STONE MJ, SAUSVILLE EA, FAY JVV et aL:A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 88:1188–1197.
  • FLAVELL DJ, FLAVELL SU, BOEHM DA et al.: Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br. J. Cancer (1995) 72:1373–1379.
  • RHODES EG, BAKER PK, RHODES JM,DAVIES JM, DUGUID JK: Autologous bone marrow transplantation for myeloma patients using PNA- and CD19-purged marrow rescue. Bone Marrow Transplant(1994) 13:795–799.
  • ROWLAND AJ, PIETERSZ GA, MCKENZIE IF: Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol brimunother (1993) 37:195–202.
  • GUILLEM VM, TORNIO M, REVERT F et al.: Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. Gene Merl (2002) 4:170–182.
  • GHETIE MA, GHETIE V, VITETTA ES: Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Chit. Cancer Res. (1999) 5:3920–3927.
  • COIFFIER B: Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin. Oncol (2002) 29(2 Supp1.6) :18–22.
  • FRIEDBERG JVV, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with ritwdmab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol (2002) 117: 828–834.
  • KIMBY E: Beyond immunochemotherapy: combinations of ritwdmab with cytokines interferon-a2a and granulocyte-macrophage colony stimulating factor. Semin. Omni (2002) 29(2 Supp1.6):7–10.
  • TREON SP, PILARSKI LM, BELCH AR et al.: CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Immunother (2002) 25:72–81.
  • NABHAN C, ROSEN ST: Conceptual aspects of combining ritwdmab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol (2002) 29(1 Supp1.2):75–80.
  • ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with ritwdmab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99:67–74.
  • JOYCE RM, KRASER CN, TETREALT JC et al.: Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B- cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Ear. HaematoL SuppL (2001) 64:56–62.
  • WILSON WH, GUTIERREZ M, O'CONNOR P et al.: The role of ritiiximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Seinin. Oncol (2002) 29(1 Supp1.2):41–47.
  • ALAS S, BONAVIDA B, EMMANOUILIDES C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and ritiiximab. Anti-Cancer Res (2000) 20:2961–2966.
  • BEHR TM, GRIESINGER F, RIGGERT J et al.: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer (2002) 94(4 Suppl.):1363–1372.
  • HENDRIX CS, DE LEON C, DILLMAN RO: Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tffixetan. Clin. Oncol Nurs. (2002) 6:144–148.
  • WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritiiximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:3262–3269.
  • WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tffixetan radioimmunotherapy versus ritwdmab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. j. Clin. Oncol (2002) 20:2453–2463.
  • KAMINSKI MS, ZELENETZ AD, PRESS OW et al: Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Clin. Oncol (2001) 19: 3918–3928.
  • GOPAL AK, RAJENDRAN JG, PETERSDORF SH et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood (2002) 99:3158–3162.
  • KORAL KF, FRANCIS IR, KROLL S, ZASADNY KR, KAMINSKI MS, WAHL RL: Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. Cancer (2002) 94(4 Suppl.):1258–1263.
  • LINDEN O, TENNVALL J, HINDORF C et al: 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol (2002) 41:297–303.
  • JUWEID ME, STADTMAUER E, HADAR G et al.: Pharmacokinetics, dosimetry, and initial therapeutic results with 1311- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Cl/n. Cancer Res. (1999) 5(10 Suppl.):3292s–3303s.
  • BARTH S: Technology evaluation: BL22, NCI. Curr. Opin. Mol. Ther. (2002) 4:72–75.
  • KREITMAN RJ, WILSON WH, BERGERON K et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345:241–247.
  • NEWTON DL, RYBACK SM: Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin. Biol. Ther. (2001) 1:995–1003.
  • NEWTON DL, HANSEN HJ, MIKULSKI SM, GOLDENBERG DM, RYBAK SM: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. B/ood(2001) 97:528–535.
  • BEHR TM, WORMANN B, GRAMATZKI M et al.: Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin. Cancer Res. (1999) 5(10 Suppl.):3304s–3314s.
  • FRENCH RR, PENNEY CA, BROWNING AC, STIRPE F, GEORGE AJ, GLENNIE MJ: Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br. J. Cancel: (1995) 71:986–994.
  • LUNDBERG BB, GRIFFITHS G, HANSEN HJ: Specific binding of sterically stabilized anti-B Cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int. Pliarin. (2000) 205:101–108.
  • TSUTSUMI Y, ONDA M, NAGATA S, LEE B, KREITMAN RJ, PASTAN I: Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Nall Acad. Sci. USA (2000) 97:8548–8553.
  • KREITMAN RJ, WILSON WH, WHITE JD et al: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Clin. Oncol (2000) 18:1622–1636.
  • ROBBINS DH, MARGULIES I, STETLER-STEVENSON M, KREITMAN RJ: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res. (2000) 6:693–700.
  • WALDMANN TA, WHITE JD, CARRASQUILLO JA et al.: Radioimmunotherapy of interleukin-2R a-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 86: 4063–4075.
  • ZHANG M, YAO Z, GARMESTANI K et al.: Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the a-emitting radionuclide, bismuth 213. Blood (2002) 100:208–216.
  • ESTEY EH, THALL PF, GILES FJ et al: Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood (2002) 99: 4343–4349.
  • ESTEY EH, GILES FJ, BERAN M et al.: Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222–4224.
  • SIEVERS EL, LINENBERGER M: Mylotarg: antibody-targeted chemotherapy comes of age. Carr. Opin. Oncol (2001) 13:522–527.
  • JURCIC JG: Antibody therapy for residual disease in acute myelogenous leukemia. Crit. Rev Oncol Heinatol (2001) 38:37–45.
  • PAGLIARO LC, LIU B, MUNKERR et al: Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin. Cancer Res (1998) 4:1971–1976.
  • BALAIAN L, BALL ED: Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leak. Res (2001) 25:1115–1125.
  • FLAVELL DJ, BOEHM DA, NOSS A, WARNES SL, FLAVELL SU: Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br. J. Cancer. (2001) 84:571–578.
  • ELLIS JH, BARBER KA, "NTT A et al.: Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. Immunol (1995) 155:925–937.
  • GOLDMACHER VS, BOURRET LA, LEVINE BA et al.: Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 84:3017–3025.
  • SIEVERS EL: Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother. Pharmacol (2000) 46:518–522.
  • APPELBAUM FR: Antibody-targeted therapy for myeloid leukemia. Semin. Hematol (1999) 36(4 Supp1.6):2–8.
  • DE KROON JF, DE PAUS RA, KLUIN-NELEMANS HC et al: Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. Exp. Hematol (1996) 24:919–926.
  • MATTHEWS DC, APPELBAUM FR, EARY JF et al.: Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD4 5 antibody, combined with cyclophosphamide and total body irradiation. Blood(1995) 85:1122–1131.
  • LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768–773.
  • KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-111) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
  • UPPENKAMP M, ENGERT A, DIEHL V, BUNJES D, HUHN D, BRITTINGER G: Monoclonal antibody therapy with CAMPATH-111 in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. Hematol (2002) 81:26–32.
  • CULL GM, HAYNES AP, BYRNE JL et al.: Preliminary experience of allogeneic stem Cell Transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br. J. Haematol (2000) 108:754–760.
  • LEWIS LD, BEELEN AP, COLE BF et al.: The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon 7-lb in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother. Pharmacol (2002) 49:375–384.
  • JAMES ND, ATHERTON PJ, JONES J, HOWIE AJ, TCHEKMEDYIAN S, CURNOW RT: A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HERZ advanced prostate cancer. Br. J. Cancer (2001) 85:152–156.
  • SUVAS S, SINGHV, SAHDEV S, VOHRA H, AGREWALA JN: Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. Biol. Chem. (2002) 277:7766–7775.
  • VOOIJS WC, OTTEN HG, VAN VLIET M et al.: B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br: J. Cancer (1997) 76:1163–1169.
  • SCHOPF RE: IDEC-114 (IDEC). Carr. Opin. Investig. Drugs (2001) 2:635–638.
  • KIRCHNER EM, GERHARDS R, VOIGTMANN R: Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann. Oncol (2002) 13:1044–1048.
  • SCHWARTZBERG LS: Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Omni Hematol (2001) 40:17–24.
  • NAUNDORF S, PREITHNER S, MAYER P et al.: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int. J. Cancer (2002) 100:101–110.
  • BAUM RP, NIESEN A, HERTEL A et al.: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (1994) 73(3 Suppi.):1121–1125.
  • SCHMOLLING J, WAGNER U, REINSBERG J, BIERSACK HJ, KREBS D: Immune reactions and survival of patients with ovarian carcinomas after administration of 1-31I-F(Ab)2 fragments of the OC 125 monoclonal antibody. Ceburtshilfe Frauenheilkd. (1995) 55:200–203.
  • MAHE MA, FUMOLEAU P, FABBRO M et al.: A Phase II study of intraperitoneal radioimmunotherapy with iodine-131 labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. (1999) 5(10 Suppl.):3249s–3253s.
  • DUSKA LR, HAMBLIN MR, MILLER JL, HASAN T: Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. I Natl. Cancer Inst. (1999) 91:1557–1563.
  • ABE H, KUROKI M, TACHIBANA K et al.: Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anti-Cancer Res. (2002) 22:1575–1580.
  • SENBA T, KUROKI M, ARAKAWA F et al.: Tumor growth suppression by a mouse/ human chimeric anti-CEA antibody and lymphokine-activated killer cells M vitro and in SCID mouse xenograft model. Anti Cancer Res. (1998) 18:17–24.
  • BEHR TM, LIERSCH T, GREINER-BECHERT L et al: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 94(4 Suppl.):1373–1381.
  • STEIN R, JUWEID M, ZHANG CH, GOLDENBERG DM: Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin. Cancer Res. (1999) 5(10 Suppl.):3199s–3206s.
  • JUWEID ME, HAJJAR G, SWAYNE LC et al.: Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer (1999) 85: 1828-1842.
  • AKAMATSU Y, MURPHY JC, NOLAN KF et al.: A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin. Cancer Res. (1998) 4:2825–2832.
  • PATRICK MR, CHESTER KA, PIETERSZ GA: In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody. Cancer Immunol Immunother. (1998) 46:229–237.
  • YCHOU M, PELEGRIN A, FAUROUS P et al.: Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer (1998) 75:615–619.
  • XU X, CLARKE P, SZALAIG et at Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. (2000) Cancer Res. 60: 4475–4484.
  • KIM JC, ROH SA, KOO KH et al: Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int. J. Cancer (2002) 97:542–547.
  • MAYER A, ISIOMPANOU E, O'MALLEY D et al.: Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res. (2000) 6:1711–1719.
  • CHESTER KA, MAYER A, BHATIAJ et al.: Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. (2000) Cancer Chemother: Pharmacol 46 (Suppl.):S8–S12.
  • STRIBBLING SM, MARTIN J, PEDLEY RB, BODEN JA, SHARMA SK, SPRINGER CJ: Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother. Pharmacol (1997) 40:277–284.
  • CASEY JL, KING DJ, CHAPLIN LC et al: Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br. J. Cancer (1996) 74:1397–1405.
  • PEDLEY RB, BODEN JA, BODENR et al: The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. Cancer (1994) 70:1126–1130.
  • MARSHALL D, PEDLEY RB, BODEN JA, BODEN R, BEGENT RH: Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br. J. Cancer (1994) 69:502–507.
  • ROBERT B, MACH JP, MANI JC et al: Cone targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor a. Cancer Res. (1996) 56:4758–4765.
  • KUROKI M, ARAKAWA F, KHARE PD et al.: Specific targeting strategies of Cancer Gene Therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res. (2000) 20:4067–4071.
  • KONISHI H, OCHIYA T, CHESTER KA et al.: Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum. Gene Ther. (1998) 9:235–248.
  • FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. j. Clin. Oncol (1999) 17:2889–2895.
  • 112IPATHI PK, QIN H, DENG S et al: Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. MM. Immunol (1998) 35:853–863.
  • SPENDLOVE L, LI L, POTTER V, CHRISTIANSEN D, LOVELAND BE, DURRANT LG: A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Ear: J. kimono' (2000) 30:2944–2953.
  • DENTON GW, DURRANT LG, HARDCASTLE JD, AUSTIN EB, SE WELL HF, ROBINS RA: Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer (1994) 57:10–14.
  • MAXWELL-ARMSTRONG CA, DURRANT LG, BUCKLEY TJ et al.: Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br: J. Cancer (2001) 84:1443–1446.
  • GAUTHEROT E, LE DOUSSAL JM, BOUHOU J et al.: Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Nucl. Med. (1998) 39:1937–1943.
  • NAKAKI M, TAKIKAWA H, YAMANAKA M: Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro. J. Int. Med. Res. (1997) 25:14–23.
  • MEREDITH RF, KHAZAELI MB, PLOTT WE et al.: Phase II study of dual 131I labeledmonoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Cita Cancer Res (1996) 2: 1811-1818.
  • KARASHIMA T, SWEENEY P, SLATON JW et al.: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Chit. Cancer Res. (2002) 8:1253–1264.
  • OVERHOLSER JP, PREWETT MC, HOOPER AT, WAKSAL HW, HICKLIN DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89:74–82.
  • PREWETT MC, HOOPER AT, BASSI R, ELLIS LM, WAKSAL HW, HICKLIN DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. (2002) 8:994–1003.
  • HERBST RS, LANGER CJ: Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol (2002) 29(1 Supp1.4):27–36.
  • LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol (2002) 29(1 Supp1.4):47–50.
  • GONZALEZ B, CASACO A, ALVAREZ P et al. Radiotoxicity of h-R3 monoclonal antibody labeled with 188Re administered intracerebrally in rats. Hum. Exp. Toxicol (2000) 19:684–692.
  • MORALES-MORALES A, DUCONGE J, CABALLERO-TORRES I, NUNEZ-GANDOLFF G, FERNANDEZ E, IZNAGA-ESCOBAR N: Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl. Med. Biol. (1999) 26:275–279.
  • SOLBACH C, ROLLER M, AHR A et al: Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int. J. Cancer (2002) 101:390–394.
  • STEINER K, HAUNSCHILD J, FARO HP, SENEKOWITSCH R: Distribution of humanized MAb 425 (EMD 62,000) in rats and specific localization in tumor-bearing nude mice. Cell. MM. Biol. (1995) 41:179–184.
  • STRAGLIOTTO G, VEGA F, STASIECKI P, GROPP P, POISSON M, DELATTRE JY: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur: J. Cancer (1996) 32A:636–640.
  • BIER H, HOFFMANN T, HAUSER U et al: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother: Pharmacol (2001) 47:519–524.
  • HAMBEK M, SOLBACH C, SCHNUERCH HG et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. (2001) 61:1045–1049.
  • PATRICK TA, KRANZ DM, ZACHARY JF, ROY EJ: Intracerebral bispecific ligand-antibody conjugate, increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer (1998) 78:470–479.
  • BOERMAN OC, TIBBEN JG, MASSUGER LF, CLAESSENS RA, CORSTENS FH: Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental M0v18 antibody in experimental ovarian cancer. Anti-Cancer Res. (1995) 15:2169–2174.
  • CRIPPA F, BOLIS G, SEREGNI E et al.: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1311- M0v18: clinical results in patients with minimal residual disease of ovarian cancer. Eur: I Cancer (1995) 31A:686–690.
  • ANDERSSON H, PALMS, LINDEGREN S et al.: Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody M0v18 in nude mice with intraperitoneal growth of human ovarian cancer. Anti-Cancer Res. (2001) 21:409–412.
  • BOUABDALLAH R, OLIVE D, MEYER P et al.: Anti-GM-CSF monoclonal antibody therapy for refractory acute leukemia. Leak. Lymphoma (1998) 30:539–549.
  • AZZOLI CG, KRUG LM, MILLER VA, KRIS MG, MASS R: Trastuzumab in the treatment of non-small cell lung cancer. &min. Oncol (2002) 29(1 Supp1.4):59–65.
  • MCKEAGE K, PERRY CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HERZ. Drugs (2002) 62:209–243.
  • O'SHAUGHNESSY J, VUKELJA SJ, MARSLAND T, KIMMEL G, RATNAM S, PIPPEN J: Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin. Breast Cancer (2002) 3 (Supp1.1) :17–20.
  • ESTEVA FJ, VALERO V, BOOSERD et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Clin. Omni (2002) 20:1800–1808.
  • MILLER KD, SISK J, ANSARIR et al: Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) (2001) 15(2 Supp1.3):38–40.
  • EIERIVIANN W: International herceptin study group: Trastuzumab combined with chemotherapy for the treatment of HERZ-positive metastatic breast cancer: pivotal trial data. Ann. Oncol (2001) 12\(Supp1.1):S57–S62.
  • PEGRAM MD, LOPEZ A, KONECNY G, SLAM ON DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. &min. Oncol (2000) 27(6 Supp1.11):21–25.
  • MANDLER R,WU C, SAUSVILLE EA et al.: Immunoconjugates of geldanamycin and anti-HERZ monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.' Natl. Cancer hut. (2000) 92: 1573–1581.
  • COLBERN GT, HILLER AJ, MUSTERER RS, WORKING PK, HENDERSON IC: Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HERZ positive human breast cancer model. J. Inorg. Biochem. (1999) 77:117–120.
  • SMALL EJ, BOK R, REESE DM, SUDILOVSKY D, FROHLICH M: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. &min. Oncol (2001) 28(4 Supp1.15):71–76.
  • DENARDO GL, O'DONNELL RT, ROSE LM, MIRICK GR, KROGER LA, DENARDO SJ: Milestones in the development of Lym-1 therapy. Hybridoma (1999) 18:1–11.
  • O'DONNELL RT, SHEN S, DENARDO SJ et al.: A Phase I study of 90Y-21T-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anti-Cancer Res (2000) 20:3647–3655.
  • O'DONNELL RT, LEIGH BR, CHRISTENSEN SD et al.: Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Brother. Radiopharm. (1999) 14:167–176.
  • O'DONNELL RT, DENARDO GL, KUKIS DL et al: A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. Nucl. Med. (1999) 40:2014–2020.
  • HU P, HORNICK JL, GLASKY MS et al: A chimeric Lym-1/interleulkin 2 fusion protein for, increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. (1996) 56:4998–5004.
  • KVALHEIM G, FUNDERUD S, KVALOY S et al.: Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. NatL Cancer Inst. (1988) 80:1322–1325.
  • DENARDO DG, XIONG CY, SHI XB, DENARDO GL, DENARDO SJ: Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Brother. Radiopharm. (2001) 16:525–535.
  • LEONARD JP, LINK BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol (2002) 29(1 Supp1.2):81–86.
  • KHAWLI LA, MILLER GK, EPSTEIN AL: Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (1994) 73(3 Suppl.):824–831.
  • HORNICK JL, SHARIFI J, KHAWLI LA et al.: A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Brother: Radiopharm. (1998) 13:255–268.
  • SHARIFI J, KHAWLI LA, HU P, KING S, EPSTEIN AL: Characterization of a phage display-derived human monoclonal antibody (NH576) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics (2001) 20: 305–312.
  • GHOSH S, CHAMPLIN RE, UENO NT et al.: Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant (2001) 28:271–275.
  • MOLICA S, MUSTO P, CHIURAZZI F et al.: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81:121–126.
  • SHOENFELD Y, FISHMAN P: Gamma-globulin inhibits tumor spread in mice. Int. Immunol (1999) 11:1247–1252.
  • MERIMSKY O, MELLER I, INBAR M, BAR-YEHUDA S, SHOENFELD Y, FISHMAN P: A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. (2002) mt. .1 Onto' 20: 839–843.
  • LINARDOU H, EPENETOS AA, DEONARAIN MP: A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. Int. J. Cancer (2000) 86:561–569.
  • SMANS KA, INGVARSSON MB, LINDGREN P et al.: Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens. Int. .1 Cancer (1999) 83:270–277.
  • SMANS KA, HOYLAERTS MF, NARISAWA S, MILLAN JL, DE BROE ME: Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. Cancer Res. (1995) 55:4383–4390.
  • RIVA P, MARANGOLO M, TISON V et al.: Radioimmunotherapy trials in germ testicular carcinoma: a Phase I study. Int. .1 Biol. Markers (1990) 5:188–194.
  • KALOFONOS HP, PAWLIKOWSKA TR, HEMINGWAY A et al.: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. Nucl. Med. (1989) 30:1636–1645.
  • AKEWANLOP C, WATANABE M, SINGH B, WALKER M, KUFE DW, HAYES DF: Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res. (2001) 61:4061–4065.
  • MOASE EH, QIW, ISHIDA T et al.: Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochlin. Biophys. (2001) 1510:43–55.
  • RICHMAN CM, DENARDO SJ: Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Grit. Rev Oncol Hematol (2001) 38:25–35.
  • SUPIOT S, FAIVRE-CHAUVET A, COUTURIER O et al.: Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labelled with iodine-131 and bismuth-213 on multiple myeloma. Cancer (2002) 94(4 Suppl.):1202–1209.
  • ENGEBRAATEN O, SIVAM G, JUELL S, FODSTAD O: Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int. .1 Cancer (2000) 88:970–976.
  • PIETERSZ GA, VVENJUN L, KRAUER K, BAKER T, WRESCHNER D, MCKENZIE IF: Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer binnunot Inanunother. (1997) 44:323–328.
  • KODAMA H, SUZUKI M, KATAYOSE Y et al.: Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Innnunol Innnunother. (2001) 50:539–548.
  • EPENETOS AA, HIRD V, LAMBERT H, MASON P, COULTER C: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J .Cynecol .Cancer (2000) 10:44–46.
  • MARAVEYAS A, STAFFORD N, ROWLINSON-BUSZA G, STEWART JS, EPENETOS AA: Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. (1995) 55:1060–1069.
  • LJUNG G, LENNERNAS B, NORDGREN H et al.: Human milk fat globule antigen 1 (HMFG1) expression in prostatic carcinoma and immunotargeting with a radiolabelled monoclonal anti-HMFG1 antibody. Anti-Cancer Res. (2000) 20:2321–2324.
  • O'DONNELL RT, DENARDO SJ, YUAN A et al.: Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. (2001) 7:1561–1568.
  • MCDEVITT MR, BARENDSWAARD E, MA D et al.: An a-particle emitting antibody ([213Bi]J59 for radioimmunotherapy of prostate cancer. Cancer Res. (2000) 60:6095–6100.
  • KAHN D, AUSTIN JC, MAGUIRE RT, MILLER SJ, GERSTBREIN J, WILLIAMS RD: A Phase II study of [9°Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother. Radiophann. (1999) 14:99–111.
  • SINHA AA, QUAST BJ, REDDY PK, ELSON MK, WILSON MJ. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anti-Cancer Res. (1999) 19:893–902.
  • SCHNEEBAUM S, TROITSA A, HADDAD R et al.: Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J. Sing. (2001) 25:1495–1498.
  • MCINTOSH DG, COLCHER D, SEEMAYER T, SMITH ML: The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe. Cancer Biother. Radiophann. (1997) 12:287–294.
  • MULLIGAN T, CARRASQUILLO JA, CHUNG Y et al.: Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. (1995) 1:1447–1454.
  • SLOVIN SF, SCHER HI, DIVGI CR et al.: Interferon-y and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. (1998) 4:643–651.
  • TEMPERO M, LEICHNER P, BARANOWSKA-KORTYLEWICZ J et al.: High-dose therapy with 9°Yttrium-labeled monoclonal antibody CC49: a Phase I trial. Clin Cancer Res. (2000) 6:3095–3102.
  • MEREDITH RF, ALVAREZ RD, PARTRIDGE EE et al.: Intraperitoneal radioimmunochemotherapy of ovarian cancer: a Phase I study. Cancer Biotite]: Radiophann. (2001) 16:305–315.
  • KASHMIRI SV, IWAHASHI M, TAMURA M, PADLAN EA, MILENIC DE, SCHLOM J: Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Grit. Rev Oncol Hematol (2001) 38:3–16.
  • GOEL A, AUGUSTINE S, BARANOWSKA-KORTYLEWICZ J et al.: Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin. Cancer Res. (2001) 7:175–184.
  • GOEL A, BERESFORD GW, COLCHER D et al.: Divalent forms of CC49 single-chain antibody constructs in Pichiapastoris: expression, purification, and characterization. Biochern. (2000) 127:829–836.
  • KELLY FJ, MILLER CR, BUCHSBAUM DJ et al.: Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitra Cancer Re.s (2000) 6:4323–4333.
  • DOMINGO RI, REILLY RM: Pm-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 9°Y-DOTA-biotin. Nucl. Med. Commun. (2000) 21:89–96.
  • JOHNSON DA, BRIGGS SL, GUTOWSKI MC, BARTON R: Anti-tumor activity of CC49-doxorubicin immunoconjugates. Anti-Cancer Res. (1995) 15:1387–1393.
  • MURRAY S, LINARDOU H: Non-cancer therapeutic antibodies. Expert Opin. Ther. Patents (2002) 12:401–417.
  • TREHU EG, MIER JW, DUBOIS JS et al: Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin. Cancer Res. (1996) 2:1341–1351.
  • COURIEL DR, HICKS K, GIRALT S, CHAIVIPLIN RE: Role of tumor necrosis factor-a inhibition with inflixiIVIAB in cancer therapy and hematopoietic stem cell transplantation. Cum Opin. Oncol. (2000) 12:582–587.
  • BREKKEN RA, OVERHOLSER JP, STASTNY VA, WALTENBERGER J, MINNA JD, THORPE PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117–5124.
  • SOH EY, EIGELBERGER MS, KIM KJ et a/.: Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in viva Surgery (2000) 128:1059–1065.
  • HUNT S: Technology evaluation: IMC-1C11, ImClone Systems. Curr. Opin. Mol. Ther. (2001) 3:418–424.
  • KLEMENT G, HUANG P, MAYERB et a/.: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Gin. Cancer Res. (2002) 8:221–232.
  • ZHANG L, YU D, HICKLIN DJ, HANNAY JA, ELLIS LM, POLLOCK RE: Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. (2002) 62:203–2042.
  • JUNG YD, MANSFIELD PF, AKAGI M et al.: Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Ear. J. Cancer (2002) 38:1133–1140.
  • POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti-av I33) antibody in patients with metastatic cancer. Cancer Biother: Radiophann. (2001) 16:125–132.
  • GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avB3. Gin. Cancer Res. (2000) 6:3056–3061.
  • TRIKHA M, ZHOU Z, TIMARJ et al.: Multiple roles for platelet GPIIb/IIIa and avI33 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. (2002) 62:2824–2833.
  • EPSTEIN AL, KHAWLI LA, HORNICK JL, TAYLOR CR: Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res. (1995) 55:2673–2680.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.